Management der progredienten Lungenfibrosen – Update 2025

Recent advances in progressive pulmonary fibrosis treatment include three major developments: Nerandomilast, a selective PDE4B inhibitor, demonstrated significant reduction in FVC decline in Phase III trials for both IPF and PPF, with improved tolerability compared to current antifibrotics and expected EMA approval in 2026. Inhaled treprostinil received FDA approval in May 2025 as the first specific therapy for PH-ILD in the US, based on the INCREASE study showing improved exercise capacity, wit